Swedish StromaBio AB

Swedish StromaBio is a clinical stage biopharma company building on more than two decades of research on mesenchymal stromal cells (MSC).

Swedish StromaBio was founded in 2018 with the aim to develop registered products based on mesenchymal stromal cells (MSC).

Historically, cell therapy has been used for transplantation purposes developed within the hospitals. With the advancement in techniques to expand and potentially change the natural function of the cells, MSC products are defined as an advanced therapy medicinal product (ATMP). StromaBio is built on a strong scientific base ranging back to the beginning of MSC-research in Sweden.

StromaBio Received the Seal of Excellence, the EU Quality label for excellent ideas worthy of funding, for our Priority project ARDS-ECMO. 

StromaBio is a subsidiary to Takura AB: www.takura.se

StromaBio is founded on a strong scientific platform of cell biology, immunology and transplantation biology. With this knowledge we aim to target conditions with a strong inflammatory component. The MSC will modulate the inflammation and induce a healthy regeneration.